Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03045120 · ClinicalTrials.gov registry record
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 118
- Enrollment target
NCT03045120 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 118 participants.
The verdict
NCT03045120 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 118 participants
- Enrollment target
Study Summary
This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and initiating first-line TKIs in routine clinical practice in the US. All treatment decisions will be determined at the discretion of the treating physician(s) and data identifying the cardiovascular and metabolic risk factors will be collected. Additional fasting blood samples (collected following 8 hours of fasting) will be collected during standard of care (SOC)/routine office visits. Additional research imaging will be performed and will be reviewed by core imaging laboratory. As the study is collecting data on management of CML, this study will not influence the prescribing or management practices at participating sites.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2022-06-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03045120
The ClinicalTrials.gov registry entry for NCT03045120 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03045120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03045120 about?
NCT03045120 is a clinical study titled "Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States". This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and initiating first-line TKIs in routine cl...
What is the current status of trial NCT03045120?
This trial is currently completed. The enrollment target is 118 participants. The study started on 2017-07-19. Estimated completion is 2022-06-20.
Who is sponsoring clinical trial NCT03045120?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.